Theravance Biopharma, Inc. (TBPH) Aandelenanalyse

Bedrijfsoverzicht

Theravance Biopharma, Inc. is a biopharmaceutical entity dedicated to the development and commercialization of therapeutic medicines within the United States, with a specific focus on respiratory treatments such as YUPELRI for chronic obstructive pulmonary disease and investigational compounds like Ampreloxetine. Operating within the healthcare sector and specifically the biotechnology industry, the company leverages specialized scientific expertise to create nebulized long-acting muscarinic antagonists and other novel drug candidates. The organization maintains a workforce of 90 employees and holds a market capitalization of $841.91 million, while generating trailing twelve-month revenues of $107.46 million. These financial metrics indicate that Theravance Biopharma operates as a mid-sized biotechnology firm with a significant valuation relative to its current revenue stream, suggesting a market that anticipates substantial future expansion from its pipeline of products. The disparity between its $841.91 million market cap and its $107.46 million annual revenue highlights a capitalization structure common in early-stage to growth-phase biotechnology companies, where investor valuation is often driven by potential future earnings rather than current profit scales.

Financiële gezondheid

The company reported trailing twelve-month revenues of $107.46 million and net income of $105.89 million, resulting in an EBITDA of -$1.976 million which reflects a specific cost structure where accounting depreciation or amortization expenses likely outweigh operational cash earnings. Despite the negative EBITDA figure, the net income remains highly positive at $105.89 million, indicating that non-cash charges or specific accounting adjustments significantly impact the bottom line compared to operational cash flow generation. The free cash flow stands at -$4.116 million, which signifies that the company is currently consuming cash to fund its research and development activities rather than generating surplus liquidity from operations. This negative cash flow position is typical for biopharmaceutical firms in the development phase but limits immediate financial flexibility for aggressive expansion without external capital. Profitability analysis reveals a gross margin of 65.2%, an operating margin of 43.6%, and a profit margin of 98.5%, demonstrating that the company retains a vast majority of revenue after all expenses are accounted for. The exceptionally high profit margin of 98.5% suggests that a significant portion of reported earnings may stem from non-operational sources or specific accounting treatments related to the company's asset base. In terms of solvency, the company holds $315.36 million in cash against $42.70 million in debt, supported by a conservative debt-to-equity ratio of 14.39%. The current ratio of 10.93 indicates an extremely robust short-term liquidity position, as the company possesses more than ten times the current assets necessary to cover its short-term liabilities. Return metrics show a Return on Equity of 44.8% and a Return on Assets of -0.5%, revealing that while the company generates significant returns on shareholder equity, the negative return on assets points to the heavy asset base or intangible costs associated with drug development.

Waarderingsbeoordeling

Valuation metrics for Theravance Biopharma show a trailing P/E ratio of 7.94 and a forward P/E of 12.07, implying that the market expects earnings to grow in the future to justify the higher multiple anticipated in the coming year. The price-to-book ratio is 2.81, indicating that the company trades at a premium of nearly three times its net asset value, which is typical for biotechnology firms with valuable intellectual property portfolios. Alternative valuation measures include a price-to-sales ratio of 7.83 and an EV/EBITDA of -288.08, suggesting that traditional earnings-based multiples are less relevant and that the valuation is heavily influenced by revenue multiples and the company's negative adjusted earnings. The stock price has fluctuated between a 52-week high of $21.03 and a 52-week low of $8.31, and without the current price explicitly listed in the data, the valuation context relies on these historical bounds to show the volatility range. The beta value of 0.17 indicates that the stock exhibits very low price volatility relative to the broader market, moving in a much less sensitive manner than typical equity indices. This low beta suggests that Theravance Biopharma's share price is less influenced by general market movements, providing a unique risk profile for portfolios seeking stability despite the inherent risks of the biotechnology sector.

Growth & Income

Revenue growth over the trailing twelve months stands at 144.7%, while earnings growth is listed as N/A, meaning the growth trajectory of profitability cannot be directly compared to revenue expansion in the current reporting period. The absence of an earnings growth rate, combined with the massive revenue increase, implies that the company is scaling its top line rapidly, likely through new product launches or market expansion, before fully optimizing its profit margins. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders, which aligns with the strategy of reinvesting all available earnings back into research, development, and commercialization efforts. This reinvestment approach is standard for biotechnology companies that prioritize funding their pipelines over providing current income to investors. The overall growth and income profile is characterized by explosive revenue expansion and a complete retention of profits to fund future growth initiatives, rather than providing immediate income returns or stable dividend payouts.